Tag: sars-cov-2 variants

1. There was a vaccine efficacy of 97.2% against symptomatic COVID-19 infection in individuals at least 7 days after their second vaccine dose. 2. Substantial and consistent declines in COVID-19 incidence corresponded to greater vaccine coverage. Evidence Rating Level: 2 (Good) Study Rundown: Beyond clinical trials, there is growing evidence of the...
1. Previous infection from SARS-CoV-2 was linked to an 84% lower incidence of reinfection. 2. Median interval between primary infection and reinfection of COVID-19 was greater than 200 days. Evidence Rating Level: 2 (Good) Study Rundown: While it has been suggested that a history of SARS-CoV-2 infection confers protection against subsequent infection,...
1. The AstraZeneca vaccine was 70.4% effective against the B.1.1.7 lineage, compared to 81.5% effective against non-B.1.1.7 lineages. 2. The neutralizing titer of the vaccinated individuals was nine times lower against B.1.1.7 than the non-B.1.1.7 (Victoria) strain in vitro. Evidence Rating Level: 1 (Excellent) Study Rundown: As vaccines are distributed worldwide, concern...